Gene · 5891
Papers1,940
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,940
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Zhenwu Decoction ameliorates experimental benign prostatic hyperplasia: association with mitochondrial quality control, oxidative stress and apoptosis regulation. | J Ethnopharmacol | 2027 | 42521001 | PubTator, text mining | PubMed |
| Combined Prognostic Value of Triglyceride-Glucose Index and Bilirubin in Drug-Eluting Stent Restenosis: From Clinical Risk Stratification to Exploratory Vascular-Cell Findings. | Cardiovasc Drugs Ther | 2026 | 42825863 | PubTator, text mining | PubMed |
| Integrated network pharmacology, molecular docking, ADMET profiling and In vitro α-amylase inhibitory evaluation of Cardiospermum halicacabum Linn. Against diabetes mellitus. | In Silico Pharmacol | 2026 | 42798543 | PubTator, text mining | PubMed |
| Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway. | Curr Cancer Drug Targets | 2026 | 42786809 | PubTator, text mining | PubMed |
| Natural product therapy in diabetic kidney disease: emerging multiomics-mediated signalling pathway and molecular target. | Chin Med | 2026 | 42778934 | PubTator, text mining | PubMed |
| Targeting S100A8/A9: a molecular gateway to oral inflammation, microglial activation and neuroinflammation. | Front Immunol | 2026 | 42707793 | PubTator, text mining | PubMed |
| Integrated Strategy Combining Real-World Data Mining, Network Pharmacology, and Molecular Docking to Decipher the Mechanism of Action of a Core Herbal Combination for Menopausal Syndrome. | Int J Womens Health | 2026 | 42670310 | PubTator, text mining | PubMed |
| Mangiferin Protects Human Dermal Fibroblasts Against UVB-Induced Photoaging by Regulating RAGE/NF-κB/p38 MAPK Signaling, Cellular Senescence, and ECM Homeostasis. | Curr Issues Mol Biol | 2026 | 42651756 | PubTator, text mining | PubMed |
| New insights into multi-endpoint toxicological profiles and potential molecular mechanisms for display-related organic light-emitting/modulating materials. | Ecotoxicol Environ Saf | 2026 | 42636667 | PubTator, text mining | PubMed |
| Material Basis and Mechanisms of Action of PuRenDan in the Treatment of Type 2 Diabetes Mellitus: An Integrated Network Pharmacology and Molecular Simulation Study. | Pharmaceuticals (Basel) | 2026 | 42515787 | PubTator, text mining | PubMed |
| Deciphering the Multi-Target Therapeutic Mechanisms of Traditional Chinese Medicine Against Alzheimer's Disease: A Network Pharmacology Perspective. | Drug Des Devel Ther | 2026 | 42504206 | PubTator, text mining | PubMed |
| Multi-Target Cardioprotective Potential of Garcinia indica Choisy in Olanzapine-Induced Cardiometabolic Dysregulation: Evidence From Computational and Experimental Insights in H9c2(2-1) Cells. | Chem Biodivers | 2026 | 42460687 | PubTator, text mining | PubMed |
| GLO1 cg26053840 Methylation Associates with Kidney Injury and Inflammatory Markers in Hospitalized Older Adults. | Life (Basel) | 2026 | 42355445 | PubTator, text mining | PubMed |
| Molecular Mechanisms of 6PPD and 6PPD-Q Toxicity in Neurodegenerative Diseases: A Network Toxicology and Experimental Validation Study. | Toxics | 2026 | 42347402 | PubTator, text mining | PubMed |
| Therapeutic potential of glycyrrhizic acid in inflammation-related diseases: from HMGB1-oriented molecular insights to preclinical application. | Arch Pharm Res | 2026 | 42307888 | PubTator, text mining | PubMed |
| PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia. | Drug Resist Updat | 2026 | 42235483 | PubTator, text mining | PubMed |
| Plasticizer-responsive molecular axes in heart failure: a subtype-aware toxicogenomic framework relevant to environmental health. | Environ Int | 2026 | 42235321 | PubTator, text mining | PubMed |
| From risk factors to molecular targets: clinical associations and molecular docking insights into phthalate-associated diabetic retinopathy. | Front Med (Lausanne) | 2026 | 42210918 | PubTator, text mining | PubMed |
| Network Pharmacology and Molecular Docking-Based Investigation of Empagliflozin's Therapeutic Potential in Chronic Kidney Disease. | Life (Basel) | 2026 | 42195274 | PubTator, text mining | PubMed |
| Understanding exosomes in diabetic wound healing. | Periodontol 2000 | 2026 | 42178716 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5891/papers